Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Genetics (2)
- Genetics and Genomics (2)
- Life Sciences (2)
- Medical Sciences (2)
- Biochemistry, Biophysics, and Structural Biology (1)
-
- Biology (1)
- Cancer Biology (1)
- Cell Biology (1)
- Cell and Developmental Biology (1)
- Enzymes and Coenzymes (1)
- European Law (1)
- Genetic Phenomena (1)
- Jurisprudence (1)
- Laboratory and Basic Science Research (1)
- Law (1)
- Medical Cell Biology (1)
- Medical Genetics (1)
- Medical Molecular Biology (1)
- Medical Specialties (1)
- Molecular Biology (1)
- Molecular Genetics (1)
- Oncology (1)
- Orthopedics (1)
- Pharmacology, Toxicology and Environmental Health (1)
- Pharmacy and Pharmaceutical Sciences (1)
- Veterinary Medicine (1)
- Institution
- Keyword
Articles 1 - 3 of 3
Full-Text Articles in Chemicals and Drugs
Ppar Agonists Down-Regulate The Expression Of Atp10c Mrna During Adipogenesis, A Peretich, Maria Cekanova Ms, Rndr, Phd, S Hurst, Sj Baek, Madhu Dahr
Ppar Agonists Down-Regulate The Expression Of Atp10c Mrna During Adipogenesis, A Peretich, Maria Cekanova Ms, Rndr, Phd, S Hurst, Sj Baek, Madhu Dahr
Maria Cekanova MS, RNDr, PhD
No abstract provided.
Evaluation Of Polymorphism At Codon 192 Of Paraoxonase 1 On Its Kinetic Behavior, Rozaida @ Poh Yuen Ying
Evaluation Of Polymorphism At Codon 192 Of Paraoxonase 1 On Its Kinetic Behavior, Rozaida @ Poh Yuen Ying
Rozaida @ Poh Yuen Ying
Human paraoxonase 1 (PON1), a High-Density Lipoprotein (HDL)-associated esterase has been implicated in slowing down the development of atherosclerosis. In the present study, kinetic and inhibition studies on PON1 were conducted to assess three parameters: the Michaelis constant (KM) and maximal rate of metabolisme (Vmax) of paraoxonase and inhibition constant (Ki) of phenylacetate. Human paraoxonase 1 (PON1) activity was measured spectrophotometrically at 405 nm, using plasma samples in basal (without added NaCl) and salt-stimulated assays with 1 M NaCl. Inhibition studies were performed using phenylacetate as an inhibitor of PON1 in basal assays, pH 8.0. Estimates of KM and Vmax …
"Publicidad E Información Sobre Los Medicamentos: Dos Conceptos Difíciles De Delimitar En El Ámbito Del Derecho Comunitario", Luis González Vaqué
"Publicidad E Información Sobre Los Medicamentos: Dos Conceptos Difíciles De Delimitar En El Ámbito Del Derecho Comunitario", Luis González Vaqué
Luis González Vaqué
La interpretación del artículo 86 de la Directiva 2001/83/CE en el sentido de que el criterio crucial para separar la publicidad de la simple información radica en el propósito perseguido, nos parece acertada: «si se quiere fomentar ‘la prescripción, la dispensación, la venta o el consumo’ de fármacos, habrá publicidad según la Directiva [2001/83/CE]; por el contrario, si se transmite un dato informativo ‘puro’, sin afán promocional, quedará exento de las reglas comunitarias sobre publicidad de medicamentos». Confirma esta orientación lo dispuesto en el artículo 86.2, que excluye de la aplicación de las reglas relativas a la publicidad ciertos tipos …